Awards and Recognition
In recent years, Frontage has been recognized for its growth and leadership by several prominent business and community organizations.
Inc. Magazine named Frontage to its 2012 list of the fastest growing private companies in the U.S. Now in its 6th year, the Inc. 5000 is an exclusive ranking that placed Frontage #74 among all Philadelphia area companies. The 2012 list represents the most comprehensive look at the most important segment of the economy—America’s independent entrepreneurs, the magazine said. With a 3-year growth rate of 77%, Frontage joins VWR International, Quincy Bioscience, and Physicians’ Pharmaceutical, among other health care companies featured on this year’s list.
In 2011 Frontage won two awards for its growth. First, came the Realizing the American Dream award, won by Founder and CEO Song Li, PhD. Dr. Li was recognized as a high-achieving immigrant entrepreneur who has made a significant contribution to the Philadelphia area economy. The award is bestowed by the nonprofit Welcoming Center for New Pennsylvanians.
The second award of 2011 was the Philadelphia SmartCEO/Clifton Gunderson Future 50 award, which recognizes the area’s 50 fastest-growing companies based on employee and revenue growth over the past three years.
For five consecutive years – from 2006 to 2010 – the company won the Philadelphia 100 award for rapid growth. The Philadelphia 100 has been the hallmark of entrepreneurial achievement in the region since 1988. Run by the Wharton Small Business Development Center, The Entrepreneurs' Forum of Greater Philadelphia, and the Philadelphia Business Journal, the project identifies and honors the 100 fastest growing, privately held entrepreneurial companies in the Greater Philadelphia Region.
As a five time winner, Frontage was named to the Philadelphia 100 Hall of Fame, joining a short list of companies whose success disqualifies them from future inclusion in the general rankings.
Stay tuned for more accolades as Frontage continues to grow in prominence and influence throughout the region and in the pharmaceutical contract research industry.